Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
NEIAFMR to be developed as the national hub for folk medicine
Furthering cell therapy ambition across oncology and autoimmune diseases
US FDA approval based on NEURO-TTRansform Phase III results
The plant is yet to start commercial operations
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Leading USA based genetic testing brand officially enters the Indian market
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Subscribe To Our Newsletter & Stay Updated
